Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprocitentan QT Interval Study
NCT04281342Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aprocitentan in resistant hypertension (RH) (4 arms), sponsored by Idorsia. Primary endpoint: Placebo-corrected change from baseline in QT interval corrected with Fridericia's formula at Day 11. Started Jan 2020; status: completed.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT04281342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04281342.